David I Quinn, MD

Title(s)Associate Professor of Medicine (Clinical Scholar)
AddressNOR 3440
Health Sciences Campus
Los Angeles CA 90089-9173
Phone+1 323 865 3956
vCardDownload vCard
    Other Positions
    Title(s)Section Head, Genitourinary (GU) Oncology, Division of Cancer Medicine and Blood Diseases in the Department of Medicine


    Collapse Biography 
    Collapse Awards and Honors
    University of New South Wales1987Gordon Lowe Memorial Prize
    University of New South Wales1987Honours First Class Bachelor of Medicine, Bachelor of Surgery
    National Health and Medical Research Council of Australia1996  - 1999Postgraduate Medical Scholarship
    Postgraduate Medical Council of New South Wales2000Distinguished Contribution Award
    St. Vincent's Clinic Foundation2000The David Wilson Travelling Fellowship
    National Health and Medical Research Council of Australia2000  - 2003Neil Hamilton Fairley Fellowship
    Royal Australasian College of Physicians2001Vincent Fairfax Family Fellowship
    USC Norris Cancer Center and Hospital2002The Spirit of Norris Award
    Castle Connolly Medical2010America's Top Doctors

    Collapse Overview 
    Collapse Overview
    David Ian Quinn MBBS Honors Class I, PhD, FRACP FACP is an international expert in the field of clinical trials and molecular correlative studies in genitourinary cancer. Dr. Quinn is the medical director of the Norris Cancer Hospital and Clinics, head of the Section of Genitourinary Medical Oncology and associate professor of Medicine in the Division of Cancer Medicine and Blood Diseases at the Keck School of Medicine of USC. Prior experience includes Directorship of the Clinical Investigation Support Office and Leadership of the Genitourinary Cancer and Developmental Therapeutics Programs for the USC Norris Comprehensive Cancer Center.

    He is a medical oncologist with focus in the field of clinical trials and molecular correlative studies in genitourinary cancer and early therapeutics. David Quinn has published more than 200 papers, reviews and chapters including recent publications in the journals Cancer Research, Clinical Cancer Research, Oncogene, Proceedings of the National Academy of Science, Journal of the National Cancer Institute, Lancet, Lancet Oncology, New England Journal of Medicine and Journal of Clinical Oncology. Dr. Quinn is a reviewer for more than 50 peer-reviewed journals and is on the editorial boards of is on the editorial boards of American Journal of Clinical Oncology, cancer.net (American Society of Clinical Oncology), Clinical Genitourinary Cancer, Bladder Cancer and Annals of Oncology. Dr. Quinn is a member of the NCI Prostate Cancer Task Force, Co-Chair for Genitourinary Cancer in the California Cancer Consortium and is SWOG organ site chair for advanced prostate cancer. He is a full member of the Department of Defense Integration Panel for Prostate Cancer Awards and has been an invited speaker in more than 40 countries.

    Dr. Quinn's current focus is on clinical trials and translation applications at USC and with SWOG and the California Cancer Consortium, where he has been principal investigator on more than 100 clinical trials for locally advanced and castrate-resistant prostate cancer, high grade urothelial cancer, advanced renal cell cancer, refractory germ cell tumors and adrenocortical carcinoma.

    Collapse Research 
    Collapse Research Activities and Funding
    NCTN - Network Lead Academic Participating Site: USC
    NIH UG1CA180830Apr 17, 2014 - Feb 28, 2025
    Role: Co-Principal Investigator
    NCI NCTN- Network Lead Academic Participating Site: USC
    NIH U10CA180830Apr 17, 2014 - Feb 28, 2019
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Albumin levels predict prognosis in advanced renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis. Urol Oncol. 2021 Aug 25. Zhou X, Fu G, Zu X, Xu Z, Li HT, D'souza A, Tulpule V, Quinn DI, Bhowmick NA, Weisenberger DJ, Liang G, Chen J. PMID: 34454823.
      View in: PubMed   Mentions:    Fields:    
    2. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med. 2021 08 19; 385(8):683-694. Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T, KEYNOTE-564 Investigators . PMID: 34407342.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    3. Identification of 22 susceptibility loci associated with testicular germ cell tumors. Nat Commun. 2021 07 23; 12(1):4487. Pluta J, Pyle LC, Nead KT, Wilf R, Li M, Mitra N, Weathers B, D'Andrea K, Almstrup K, Anson-Cartwright L, Benitez J, Brown CD, Chanock S, Chen C, Cortessis VK, Ferlin A, Foresta C, Gamulin M, Gietema JA, Grasso C, Greene MH, Grotmol T, Hamilton RJ, Haugen TB, Hauser R, Hildebrandt MAT, Johnson ME, Karlsson R, Kiemeney LA, Lessel D, Lothe RA, Loud JT, Loveday C, Martin-Gimeno P, Meijer C, Nsengimana J, Quinn DI, Rafnar T, Ramdas S, Richiardi L, Skotheim RI, Stefansson K, Turnbull C, Vaughn DJ, Wiklund F, Wu X, Yang D, Zheng T, Wells AD, Grant SFA, Rajpert-De Meyts E, Schwartz SM, Bishop DT, McGlynn KA, Kanetsky PA, Nathanson KL, Testicular Cancer Consortium . PMID: 34301922.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    4. Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors. Invest New Drugs. 2021 May 24. Ashkar R, Feldman DR, Adra N, Zaid MA, Funt SA, Althouse SK, Perkins SM, Snow CI, Lazzara KM, Sego LM, Quinn DI, Hanna NH, Einhorn LH, Albany C. PMID: 34031784.
      View in: PubMed   Mentions:    Fields:    
    5. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2021 06; 22(6):872-882. Yu EY, Petrylak DP, O'Donnell PH, Lee JL, van der Heijden MS, Loriot Y, Stein MN, Necchi A, Kojima T, Harrison MR, Hoon Park S, Quinn DI, Heath EI, Rosenberg JE, Steinberg J, Liang SY, Trowbridge J, Campbell M, McGregor B, Balar AV. PMID: 33991512.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    6. ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups. ESMO Open. 2021 Jun; 6(3):100105. Quinn DI, Ng CF, Grande E, Kwon TG, Linke R, Lee JL, Rosbrook B, Thakur MN, Eto M, Gross-Goupil M. PMID: 33901868.
      View in: PubMed   Mentions:
    7. A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide. ESMO Open. 2021 Apr; 6(2):100082. Petrylak DP, Vaishampayan UN, Patel KR, Higano CS, Albany C, Dawson NA, Mehlhaff BA, Quinn DI, Nordquist LT, Wagner VJ, Siegel J, Trandafir L, Sartor O. PMID: 33744812.
      View in: PubMed   Mentions:
    8. Tetraspanin18 regulates angiogenesis through VEGFR2 and Notch pathways. Biol Open. 2021 02 25; 10(2). Li GX, Zhang S, Liu R, Singh B, Singh S, Quinn DI, Crump G, Gill PS. PMID: 32694189.
      View in: PubMed   Mentions:
    9. Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216). Clin Cancer Res. 2021 Apr 01; 27(7):1967-1973. Goldkorn A, Tangen C, Plets M, Morrison GJ, Cunha A, Xu T, Pinski JK, Ingles SA, Triche T, Harzstark AL, Kohli M, MacVicar GR, Vaena DA, Crispino AW, McConkey DJ, Lara PN, Hussain MHA, Quinn DI, Vogelzang NJ, Thompson IM, Agarwal N. PMID: 33500355.
      View in: PubMed   Mentions:    Fields:    
    10. Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879. Invest New Drugs. 2021 Jun; 39(3):812-820. Quinn DI, Tsao-Wei DD, Twardowski P, Aparicio AM, Frankel P, Chatta G, Wright JJ, Groshen SG, Khoo S, Lenz HJ, Lara PN, Gandara DR, Newman E. PMID: 33409898.
      View in: PubMed   Mentions: 1     Fields:    
    11. Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer. Clin Cancer Res. 2021 03 01; 27(5):1391-1398. Chalfin HJ, Pramparo T, Mortazavi A, Niglio SA, Schonhoft JD, Jendrisak A, Chu YL, Richardson R, Krupa R, Anderson AKL, Wang Y, Dittamore R, Pal SK, Lara PN, Stein MN, Quinn DI, Steinberg SM, Cordes LM, Ley L, Mallek M, Sierra Ortiz O, Costello R, Cadena J, Diaz C, Gulley JL, Dahut WL, Streicher H, Wright JJ, Trepel JB, Bottaro DP, Apolo AB. PMID: 33262136.
      View in: PubMed   Mentions:    Fields:    
    12. Use of Wearable Activity Tracker in Patients With Cancer Undergoing Chemotherapy: Toward Evaluating Risk of Unplanned Health Care Encounters. JCO Clin Cancer Inform. 2020 09; 4:839-853. Nilanon T, Nocera LP, Martin AS, Kolatkar A, May M, Hasnain Z, Ueno NT, Yennu S, Alexander A, Mejia AE, Boles RW, Li M, Lee JSH, Hanlon SE, Cozzens Philips FA, Quinn DI, Newton PK, Broderick J, Shahabi C, Kuhn P, Nieva JJ. PMID: 32970482.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    13. Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma. Eur Urol. 2020 12; 78(6):916-924. Lyou Y, Grivas P, Rosenberg JE, Hoffman-Censits J, Quinn DI, P Petrylak D, Galsky M, Vaishampayan U, De Giorgi U, Gupta S, Burris H, Rearden J, Li A, Wang H, Reyes M, Moran S, Daneshmand S, Bajorin D, Pal SK. PMID: 32847703.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. Eligibility Criteria and Endpoints in Metastatic Renal Cell Carcinoma Trials. Am J Clin Oncol. 2020 08; 43(8):559-566. Wong SE, Quinn DI, Bjarnason GA, North SA, Sridhar SS. PMID: 32398404.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. Cardiac Power Output Index and Severe Primary Graft Dysfunction After Heart Transplantation. J Cardiothorac Vasc Anesth. 2021 Feb; 35(2):398-403. Lim HS, Ranasinghe A, Chue C, Quinn D, Mukadam M, Mascaro J. PMID: 32747204.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    16. Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma. Invest New Drugs. 2020 12; 38(6):1807-1814. McGregor BA, Gordon M, Flippot R, Agarwal N, George S, Quinn DI, Rogalski M, Hawthorne T, Keler T, Choueiri TK. PMID: 32472319.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    17. Evaluating Changes in Immune Function and Bone Microenvironment During Radium-223 Treatment of Patients with Castration-Resistant Prostate Cancer. Cancer Biother Radiopharm. 2020 Sep; 35(7):485-489. Dorff TB, Stein C, Kortylewski M, Posadas E, Synold T, Quinn D. PMID: 32366119.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    18. EphrinB2 expression in prostate adenocarcinoma: Implications for targeted therapy. Pathol Res Pract. 2020 Jun; 216(6):152967. Gupta C, Sali A, Ma B, Jackovich A, Sadeghi S, Quinn D, Gill P, Gill I. PMID: 32362422.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    19. Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer. Ann Oncol. 2020 07; 31(7):930-941. Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM, Chi KN, De Bono JS, Araujo JC, Logothetis C, Eisenberger MA, Quinn DI, Fizazi K, Morris MJ, Higano CS, Tannock IF, Small EJ, Kelly WK. PMID: 32289380.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    20. Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. J Clin Oncol. 2020 06 01; 38(16):1797-1806. Galsky MD, Mortazavi A, Milowsky MI, George S, Gupta S, Fleming MT, Dang LH, Geynisman DM, Walling R, Alter RS, Kassar M, Wang J, Gupta S, Davis N, Picus J, Philips G, Quinn DI, Haines GK, Hahn NM, Zhao Q, Yu M, Pal SK. PMID: 32271672.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    21. Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. Cancer. 2020 06 01; 126(11):2597-2606. Pal SK, Bajorin D, Dizman N, Hoffman-Censits J, Quinn DI, Petrylak DP, Galsky MD, Vaishampayan U, De Giorgi U, Gupta S, Burris HA, Soifer HS, Li G, Wang H, Dambkowski CL, Moran S, Daneshmand S, Rosenberg JE. PMID: 32208524.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    22. Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data. Cancer. 2020 06 15; 126(12):2935-2937. Higano CS, Armstrong AJ, Sartor O, Vogelzang NJ, Kantoff PW, McLeod DG, Pieczonka CM, Penson DF, Shore ND, Vacirca J, Concepcion RS, Tutrone RF, Nordquist LT, Quinn DI, Kassabian V, Scholz MC, Harmon M, Tyler RC, Chang NN, Tang H, Cooperberg MR. PMID: 32154908.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2021 03; 24(1):61-68. Gross ME, Agus DB, Dorff TB, Pinski JK, Quinn DI, Castellanos O, Gilmore P, Shih JC. PMID: 32123315.
      View in: PubMed   Mentions: 4     Fields:    
    24. Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. Prostate Cancer Prostatic Dis. 2020 09; 23(3):517-526. Sartor O, Armstrong AJ, Ahaghotu C, McLeod DG, Cooperberg MR, Penson DF, Kantoff PW, Vogelzang NJ, Hussain A, Pieczonka CM, Shore ND, Quinn DI, Small EJ, Heath EI, Tutrone RF, Schellhammer PF, Harmon M, Chang NN, Sheikh NA, Brown B, Freedland SJ, Higano CS. PMID: 32111923.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    25. Cancer transcriptomic profiling from rapidly enriched circulating tumor cells. Int J Cancer. 2020 05 15; 146(10):2845-2854. Morrison GJ, Cunha AT, Jojo N, Xu Y, Xu Y, Kwok E, Robinson P, Dorff T, Quinn D, Carpten J, Manojlovic Z, Goldkorn A. PMID: 32037533.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    26. Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2020 09; 23(3):486-493. Wong RL, Duong MT, Tangen CM, Agarwal N, Cheng HH, Vogelzang NJ, Hussain M, Thompson IM, Quinn DI, Yu EY. PMID: 32055002.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    27. Protocol for a multi-centre, definitive randomised controlled trial of the effectiveness of Individual Placement and Support for employment support among people with alcohol and drug dependence. Trials. 2020 Feb 11; 21(1):167. Marsden J, Anders P, Clark H, Colocassis K, Eastwood B, Knight J, Melaugh A, Quinn D, Wright V, Stannard J. PMID: 32046765.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    28. Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria. Theranostics. 2020; 10(7):3254-3262. Velez EM, Desai B, Ji L, Quinn DI, Colletti PM, Jadvar H. PMID: 32194866.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    29. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. J Clin Oncol. 2020 04 01; 38(10):1041-1049. Rosenberg J, Sridhar SS, Zhang J, Smith D, Ruether D, Flaig TW, Baranda J, Lang J, Plimack ER, Sangha R, Heath EI, Merchan J, Quinn DI, Srinivas S, Milowsky M, Wu C, Gartner EM, Zuo P, Melhem-Bertrandt A, Petrylak DP. PMID: 32031899.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    30. Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies. Clin Genitourin Cancer. 2020 10; 18(5):351-360.e3. Tafuri A, Smith DD, Cacciamani GE, Cole S, Shakir A, Sadeghi S, Vogelzang NJ, Quinn D, Gill PS, Gill IS. PMID: 32146152.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    31. Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. JNCI Cancer Spectr. 2020 Apr; 4(2):pkaa003. Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM, Chi KN, De Bono JS, Araujo JC, Logothetis C, Eisenberger MA, Quinn DI, Fizazi K, Morris MJ, Higano CS, Tannock IF, Small EJ, Kelly WK. PMID: 32368717.
      View in: PubMed   Mentions:
    32. Chemoradiation for Management of Locally Recurrent or Residual Bladder Cancer: A Case Series and Review of the Literature. Clin Genitourin Cancer. 2020 08; 18(4):e473-e477. Ballas L, Wei O, Daneshmand S, Schuckman A, Djaladat H, Aron M, D'Souza A, Quinn D, Dorff TB. PMID: 32044240.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    33. Tetraspanin18 regulates angiogenesis through VEGFR2 and Notch pathways. Biol Open. 2020 Jan 01. Li GX, Zhang S, Liu R, Singh B, Singh S, Quinn DI, Crump G, Gill PS. PMID: 34004729.
      View in: PubMed   Mentions:
    34. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). J Immunother Cancer. 2019 12 20; 7(1):354. Rini BI, Battle D, Figlin RA, George DJ, Hammers H, Hutson T, Jonasch E, Joseph RW, McDermott DF, Motzer RJ, Pal SK, Pantuck AJ, Quinn DI, Seery V, Voss MH, Wood CG, Wood LS, Atkins MB. PMID: 31856918.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    35. Radium-223 mechanism of action: implications for use in treatment combinations. Nat Rev Urol. 2019 12; 16(12):745-756. Morris MJ, Corey E, Guise TA, Gulley JL, Kevin Kelly W, Quinn DI, Scholz A, Sgouros G. PMID: 31712765.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimals
    36. Editorial Comment. J Urol. 2020 02; 203(2):336-337. D'Souza AA, Quinn DI. PMID: 31661381.
      View in: PubMed   Mentions:    Fields:    
    37. Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib. Clin Cancer Res. 2019 12 15; 25(24):7381-7387. Ulaner GA, Saura C, Piha-Paul SA, Mayer I, Quinn D, Jhaveri K, Stone B, Shahin S, Mann G, Dujka M, Bryce R, Meric-Bernstam F, Solit DB, Hyman DM. PMID: 31548342.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    38. Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. Cancer. 2019 12 01; 125(23):4172-4180. Higano CS, Armstrong AJ, Sartor AO, Vogelzang NJ, Kantoff PW, McLeod DG, Pieczonka CM, Penson DF, Shore ND, Vacirca J, Concepcion RS, Tutrone RF, Nordquist LT, Quinn DI, Kassabian V, Scholz MC, Harmon M, Tyler RC, Chang NN, Tang H, Cooperberg MR. PMID: 31483485.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    39. p53 nuclear accumulation as an early indicator of lethal prostate cancer. Br J Cancer. 2019 10; 121(7):578-583. Quinn DI, Stricker PD, Kench JG, Grogan J, Haynes AM, Henshall SM, Grygiel JJ, Delprado W, Turner JJ, Horvath LG, Mahon KL. PMID: 31409910.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    40. Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy. Cancer. 2019 11 01; 125(21):3853-3863. Barzi A, Lara PN, Tsao-Wei D, Yang D, Gill IS, Daneshmand S, Klein EA, Pinski JK, Penson DF, Quinn DI, Sadeghi S. PMID: 31398279.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    41. Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653). J Clin Oncol. 2019 10 10; 37(29):2682-2688. Sadeghi S, Groshen SG, Tsao-Wei DD, Parikh R, Mortazavi A, Dorff TB, Kefauver C, Hoimes C, Doyle L, Quinn DI, Newman E, Lara PN. PMID: 31390274.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    42. A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma. Invest New Drugs. 2019 08; 37(4):755-762. Xie H, Yin J, Shah MH, Menefee ME, Bible KC, Reidy-Lagunes D, Kane MA, Quinn DI, Gandara DR, Erlichman C, Adjei AA. PMID: 31172443.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    43. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol. 2019 06 01; 30(6):970-976. Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Nam K, Frenkl TL, Perini RF, de Wit R, Bajorin DF. PMID: 31050707.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCTClinical Trials
    44. Local Injection of Submicron Particle Docetaxel is Associated with Tumor Eradication, Reduced Systemic Toxicity and an Immunologic Response in Uro-Oncologic Xenografts. Cancers (Basel). 2019 Apr 24; 11(4). Maulhardt HA, Hylle L, Frost MV, Tornio A, Dafoe S, Drummond L, Quinn DI, Kamat AM, diZerega GS. PMID: 31022918.
      View in: PubMed   Mentions:
    45. Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with 18F-FDG PET/CT. J Nucl Med. 2019 11; 60(11):1524-1530. Jadvar H, Velez EM, Desai B, Ji L, Colletti PM, Quinn DI. PMID: 30926649.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    46. Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC). Clin Genitourin Cancer. 2019 08; 17(4):241-247.e1. Dorff TB, Quinn DI, Pinski JK, Goldkorn A, Sadeghi S, Tsao-Wei D, Groshen S, Kuhn P, Gross ME. PMID: 31227432.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsCTClinical Trials
    47. Multiparametric liquid biopsy analysis in metastatic prostate cancer. JCI Insight. 2019 03 07; 4(5). Hodara E, Morrison G, Cunha A, Zainfeld D, Xu T, Xu Y, Dempsey PW, Pagano PC, Bischoff F, Khurana A, Koo S, Ting M, Cotter PD, Moore MW, Gunn S, Usher J, Rabizadeh S, Danenberg P, Danenberg K, Carpten J, Dorff T, Quinn D, Goldkorn A. PMID: 30702443.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    48. Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib - Results of NCI/CTEP Protocol 9048. Kidney Cancer. 2019 Feb 05; 3(1):51-61. Semrad TJ, Groshen S, Luo C, Pal S, Vaishampayan U, Joshi M, Quinn DI, Mack PC, Gandara DR, Lara PN. PMID: 30854497.
      View in: PubMed   Mentions:
    49. Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2019 02; 566(7745):E11-E12. Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB. PMID: 30755741.
      View in: PubMed   Mentions: 2     Fields:    
    50. Accurate blood pressure during patient arm movement: the Welch Allyn Connex Spot Monitor's SureBP algorithm. Blood Press Monit. 2019 Feb; 24(1):42-44. Alpert BS, Quinn D, Kinsley M, Whitaker T, John TT. PMID: 30586341.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    51. Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy. Int J Radiat Oncol Biol Phys. 2019 05 01; 104(1):50-60. Ballas LK, Luo C, Chung E, Kishan AU, Shuryak I, Quinn DI, Dorff T, Jhimlee S, Chiu R, Abreu A, Jennelle R, Aron M, Groshen S. PMID: 30605751.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    52. Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. J Clin Oncol. 2019 02 10; 37(5):403-410. Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM, Chi KN, Araujo JC, Logothetis C, Quinn DI, Fizazi K, Morris MJ, Eisenberger MA, George DJ, De Bono JS, Higano CS, Tannock IF, Small EJ, Kelly WK. PMID: 30576268.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    53. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann Oncol. 2018 12 01; 29(12):2371-2378. Gross-Goupil M, Kwon TG, Eto M, Ye D, Miyake H, Seo SI, Byun SS, Lee JL, Master V, Jin J, DeBenedetto R, Linke R, Casey M, Rosbrook B, Lechuga M, Valota O, Grande E, Quinn DI. PMID: 30346481.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCTClinical Trials
    54. Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder cancer. Urol Oncol. 2019 01; 37(1):1-11. Bazargani ST, Clifford TG, Djaladat H, Schuckman AK, Wayne K, Miranda G, Cai J, Sadeghi S, Dorff T, Quinn DI, Daneshmand S. PMID: 30470611.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    55. Impact of timing of administration of bone supportive therapy on pain palliation from radium-223. Cancer Treat Res Commun. 2019; 18:100114. Yap KK, Wong W, Ji L, Groshen S, Quinn DI, Bryce AH, Dorff TB. PMID: 30529990.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    56. SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer. World J Urol. 2019 Jan; 37(1):95-105. Merseburger AS, Apolo AB, Chowdhury S, Hahn NM, Galsky MD, Milowsky MI, Petrylak D, Powles T, Quinn DI, Rosenberg JE, Siefker-Radtke A, Sonpavde G, Sternberg CN. PMID: 30238401.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    57. Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421). J Patient Rep Outcomes. 2017; 2:27. Unger JM, Griffin K, Donaldson GW, Baranowski KM, Good MJ, Reburiano E, Hussain M, Monk PJ, Van Veldhuizen PJ, Carducci MA, Higano CS, Lara PN, Tangen CM, Quinn DI, Wade JL, Vogelzang NJ, Thompson IM, Moinpour CM. PMID: 29951640.
      View in: PubMed   Mentions:
    58. Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival. Clin Cancer Res. 2018 10 01; 24(19):4662-4671. Antonarakis ES, Small EJ, Petrylak DP, Quinn DI, Kibel AS, Chang NN, Dearstyne E, Harmon M, Campogan D, Haynes H, Vu T, Sheikh NA, Drake CG. PMID: 29858218.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    59. Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations. Cancer Discov. 2018 07; 8(7):812-821. Pal SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn DI, Galsky MD, Wolf J, Dittrich C, Keam B, Delord JP, Schellens JHM, Gravis G, Medioni J, Maroto P, Sriuranpong V, Charoentum C, Burris HA, Grünwald V, Petrylak D, Vaishampayan U, Gez E, De Giorgi U, Lee JL, Voortman J, Gupta S, Sharma S, Mortazavi A, Vaughn DJ, Isaacs R, Parker K, Chen X, Yu K, Porter D, Graus Porta D, Bajorin DF. PMID: 29848605.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    60. Low-dimensional dynamical characterization of human performance of cancer patients using motion data. Clin Biomech (Bristol, Avon). 2018 07; 56:61-69. Hasnain Z, Li M, Dorff T, Quinn D, Ueno NT, Yennu S, Kolatkar A, Shahabi C, Nocera L, Nieva J, Kuhn P, Newton PK. PMID: 29803824.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    61. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. Eur Urol. 2018 11; 74(5):611-620. Sun M, Marconi L, Eisen T, Escudier B, Giles RH, Haas NB, Harshman LC, Quinn DI, Larkin J, Pal SK, Powles T, Ryan CW, Sternberg CN, Uzzo R, Choueiri TK, Bex A. PMID: 29784193.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    62. Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421. Cancer Treat Res Commun. 2018; 16:18-23. Lara PN, Plets M, Tangen C, Gertz E, Vogelzang NJ, Hussain M, Twardowski PW, Garzotto MG, Monk JP, Carducci M, Goldkorn A, Mack PC, Thompson I, Van Loan M, Quinn DI. PMID: 31298998.
      View in: PubMed   Mentions: 2     Fields:    
    63. Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol. 2018 05 20; 36(15):1498-1504. Hussain M, Tangen CM, Thompson IM, Swanson GP, Wood DP, Sakr W, Dawson NA, Haas NB, Flaig TW, Dorff TB, Lin DW, Crawford ED, Quinn DI, Vogelzang NJ, Glode LM. PMID: 29624463.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    64. Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. J Clin Oncol. 2018 06 01; 36(16):1579-1587. Vaughn DJ, Bellmunt J, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Li H, Perini RF, Bajorin DF, de Wit R. PMID: 29590008.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    65. Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET. Future Oncol. 2018 Mar; 14(6):527-536. Flanders SC, Kim J, Wilson S, Braziunas J, Greenfield S, Billimek J, Lechpammer S, Lin DW, Karsh L, Quinn DI, Shevrin D, Shore ND, Symanowski JT, Penson DF. PMID: 29417827.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    66. Active Surveillance for Prostate Cancer: Are We Failing Latino Patients at a Large Safety Net Hospital? Clin Genitourin Cancer. 2018 08; 16(4):e719-e727. Ballas LK, Kraus R, Ji L, Groshen S, Stern MC, Gill I, Quinn DI, Chung E, Abreu A, Hamilton AS. PMID: 29483045.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    67. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018 02 08; 554(7691):189-194. Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB. PMID: 29420467.
      View in: PubMed   Mentions: 159     Fields:    Translation:HumansCTClinical Trials
    68. Smoke-Free Multi-unit Housing Policies Show Promise in Reducing Secondhand Smoke Exposure Among Racially and Ethnically Diverse, Low-Income Seniors. J Immigr Minor Health. 2017 12; 19(6):1281-1289. Hollar TL, Cook N, Quinn D, Phillips T, DeLucca M. PMID: 27189486.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansPHPublic Health
    69. The evolution of chemotherapy for the treatment of prostate cancer. Ann Oncol. 2017 Nov 01; 28(11):2658-2669. Quinn DI, Sandler HM, Horvath LG, Goldkorn A, Eastham JA. PMID: 29045523.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    70. Appropriate Use Criteria for 18F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease. J Nucl Med. 2017 12; 58(12):2026-2037. Jadvar H, Colletti PM, Delgado-Bolton R, Esposito G, Krause BJ, Iagaru AH, Nadel H, Quinn DI, Rohren E, Subramaniam RM, Zukotynski K, Kauffman J, Ahuja S, Griffeth L. PMID: 29025980.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    71. Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870). Clin Cancer Res. 2017 Dec 01; 23(23):7199-7208. Pili R, Quinn DI, Hammers HJ, Monk P, George S, Dorff TB, Olencki T, Shen L, Orillion A, Lamonica D, Fragomeni RS, Szabo Z, Hutson A, Groman A, Perkins SM, Piekarz R, Carducci MA. PMID: 28939740.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCellsCTClinical Trials
    72. Isolation of exosomes from whole blood by integrating acoustics and microfluidics. Proc Natl Acad Sci U S A. 2017 10 03; 114(40):10584-10589. Wu M, Ouyang Y, Wang Z, Zhang R, Huang PH, Chen C, Li H, Li P, Quinn D, Dao M, Suresh S, Sadovsky Y, Huang TJ. PMID: 28923936.
      View in: PubMed   Mentions: 130     Fields:    Translation:Cells
    73. Baseline Glomerular Filtration Rate and Cisplatin- Induced Renal Toxicity in Urothelial Cancer Patients. Clin Genitourin Cancer. 2017 Sep 06. Loh JM, Tran AL, Ji L, Groshen S, Daneshmand S, Schuckman A, Quinn DI, Dorff TB. PMID: 28958673.
      View in: PubMed   Mentions: 1     Fields:    
    74. Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. Cancer. 2017 Dec 01; 123(23):4566-4573. Dorff TB, Longmate JA, Pal SK, Stadler WM, Fishman MN, Vaishampayan UN, Rao A, Pinksi JK, Hu JS, Quinn DI, Lara PN. PMID: 28832978.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    75. Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC). Clin Genitourin Cancer. 2017 Jul 14. Gross ME, Dorff TB, Quinn DI, Diaz PM, Castellanos OO, Agus DB. PMID: 28826933.
      View in: PubMed   Mentions: 2     Fields:    
    76. Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment. Clin Adv Hematol Oncol. 2017 Jul; 15(7):543-551. Yu SS, Ballas LK, Skinner EC, Dorff TB, Sadeghi S, Quinn DI. PMID: 28749918.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    77. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions. Ann Oncol. 2017 Jul 01; 28(7):1484-1494. Atkins MB, Clark JI, Quinn DI. PMID: 28383639.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimals
    78. A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer. Clin Genitourin Cancer. 2017 12; 15(6):742-749. Yu SS, Athreya K, Liu SV, Schally AV, Tsao-Wei D, Groshen S, Quinn DI, Dorff TB, Xiong S, Engel J, Pinski J. PMID: 28668277.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCellsCTClinical Trials
    79. Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease. Clin Adv Hematol Oncol. 2017 Jun; 15(6):466-477. Yu SS, Dorff TB, Ballas LK, Sadeghi S, Skinner EC, Quinn DI. PMID: 28749907.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    80. Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer. 2017 12; 15(6):635-641. Sonpavde G, Pond GR, Plets M, Tangen CM, Hussain MHA, Lara PN, Goldkorn A, Garzotto MG, Mack PC, Higano CS, Vogelzang NJ, Thompson IM, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Quinn DI. PMID: 28579151.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    81. Access to high-volume surgeons and the opportunity cost of performing radical prostatectomy by low-volume providers. Urol Oncol. 2017 07; 35(7):459.e15-459.e24. Barzi A, Klein EA, Daneshmand S, Gill I, Quinn DI, Sadeghi S. PMID: 28284890.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    82. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017 03 16; 376(11):1015-1026. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF, KEYNOTE-045 Investigators . PMID: 28212060.
      View in: PubMed   Mentions: 714     Fields:    Translation:HumansCTClinical Trials
    83. Comparative effectiveness of screening strategies for colorectal cancer. Cancer. 2017 05 01; 123(9):1516-1527. Barzi A, Lenz HJ, Quinn DI, Sadeghi S. PMID: 28117881.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    84. Robotic salvage retroperitoneal and pelvic lymph node dissection for 'node-only' recurrent prostate cancer: technique and initial series. BJU Int. 2017 09; 120(3):401-408. Abreu A, Fay C, Park D, Quinn D, Dorff T, Carpten J, Kuhn P, Gill P, Almeida F, Gill I. PMID: 27981731.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    85. Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study. Cancer Chemother Pharmacol. 2017 Feb; 79(2):339-351. Sarantopoulos J, Mita AC, He A, Wade JL, Hsueh CT, Morris JC, Lockhart AC, Quinn DI, Hwang J, Mier J, Zhang W, Wack C, Yin J, Clot PF, Rixe O. PMID: 28058445.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    86. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017 01 07; 389(10064):67-76. Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF, IMvigor210 Study Group . PMID: 27939400.
      View in: PubMed   Mentions: 469     Fields:    Translation:HumansCTClinical Trials
    87. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. J Immunother Cancer. 2016; 4:81. Rini BI, McDermott DF, Hammers H, Bro W, Bukowski RM, Faba B, Faba J, Figlin RA, Hutson T, Jonasch E, Joseph RW, Leibovich BC, Olencki T, Pantuck AJ, Quinn DI, Seery V, Voss MH, Wood CG, Wood LS, Atkins MB. PMID: 27891227.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    88. What Medical, Urologic, and Radiation Oncologists Want from Molecular Imaging of Prostate Cancer. J Nucl Med. 2016 Oct; 57(Suppl 3):6S-12S. Ballas LK, de Castro Abreu AL, Quinn DI. PMID: 27694176.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    89. Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection. Onco Targets Ther. 2016; 9:5825-5837. Yu SS, Quinn DI, Dorff TB. PMID: 27713636.
      View in: PubMed   Mentions:
    90. Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research. Future Oncol. 2016 Dec; 12(23):2689-2699. Penson DF, Lin DW, Karsh L, Quinn DI, Shevrin DH, Shore N, Symanowski JT, Brown B, Forer D, Wong EK, Flanders SC. PMID: 27528114.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    91. Safety and feasibility of fasting in combination with platinum-based chemotherapy. BMC Cancer. 2016 06 10; 16:360. Dorff TB, Groshen S, Garcia A, Shah M, Tsao-Wei D, Pham H, Cheng CW, Brandhorst S, Cohen P, Wei M, Longo V, Quinn DI. PMID: 27282289.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    92. Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. J Clin Oncol. 2016 07 20; 34(21):2478-83. Feldman DR, Hu J, Dorff TB, Lim K, Patil S, Woo KM, Carousso M, Hughes A, Sheinfeld J, Bains M, Daneshmand S, Ketchens C, Bajorin DF, Bosl GJ, Quinn DI, Motzer RJ. PMID: 27185842.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    93. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. J Clin Oncol. 2016 05 10; 34(14):1652-9. Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP, Hussain M, Vogelzang NJ, Thompson IM, Chi KN, de Bono J, Armstrong AJ, Eisenberger MA, Fandi A, Li S, Araujo JC, Logothetis CJ, Quinn DI, Morris MJ, Higano CS, Tannock IF, Small EJ. PMID: 26951312.
      View in: PubMed   Mentions: 91     Fields:    Translation:Humans
    94. Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. J Clin Oncol. 2016 05 01; 34(13):1500-9. Petrylak DP, Tagawa ST, Kohli M, Eisen A, Canil C, Sridhar SS, Spira A, Yu EY, Burke JM, Shaffer D, Pan CX, Kim JJ, Aragon-Ching JB, Quinn DI, Vogelzang NJ, Tang S, Zhang H, Cavanaugh CT, Gao L, Kauh JS, Walgren RA, Chi KN. PMID: 26926681.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    95. Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile Cancer. Clin Genitourin Cancer. 2016 10; 14(5):450-456.e1. Dorff TB, Schuckman AK, Schwartz R, Rashad S, Bulbul A, Cai J, Pinski J, Ma Y, Danenberg K, Skinner E, Quinn DI. PMID: 26935231.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    96. Fabrication of conductive gelatin methacrylate-polyaniline hydrogels. Acta Biomater. 2016 Mar; 33:122-30. Wu Y, Chen YX, Yan J, Quinn D, Dong P, Sawyer SW, Soman P. PMID: 26821341.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCells
    97. AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth. Prostate. 2016 May; 76(6):597-608. Hu BR, Fairey AS, Madhav A, Yang D, Li M, Groshen S, Stephens C, Kim PH, Virk N, Wang L, Martin SE, Erho N, Davicioni E, Jenkins RB, Den RB, Xu T, Xu Y, Gill IS, Quinn DI, Goldkorn A. PMID: 26771938.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    98. Prostatectomy at high-volume centers improves outcomes and lowers the costs of care for prostate cancer. Prostate Cancer Prostatic Dis. 2016 Mar; 19(1):84-91. Barzi A, Klein EA, Dorff TB, Quinn DI, Sadeghi S. PMID: 26666409.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    99. Renal-Cell Cancer--Targeting an Immune Checkpoint or Multiple Kinases. N Engl J Med. 2015 Nov 05; 373(19):1872-4. Quinn DI, Lara PN. PMID: 26406149.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    100. Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†. Ann Oncol. 2015 Dec; 26(12):2392-8. Kramar A, Negrier S, Sylvester R, Joniau S, Mulders P, Powles T, Bex A, Bonnetain F, Bossi A, Bracarda S, Bukowski R, Catto J, Choueiri TK, Crabb S, Eisen T, El Demery M, Fitzpatrick J, Flamand V, Goebell PJ, Gravis G, Houédé N, Jacqmin D, Kaplan R, Malavaud B, Massard C, Melichar B, Mourey L, Nathan P, Pasquier D, Porta C, Pouessel D, Quinn D, Ravaud A, Rolland F, Schmidinger M, Tombal B, Tosi D, Vauleon E, Volpe A, Wolter P, Escudier B, Filleron T, DATECAN Renal Cancer group . PMID: 26371288.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    101. Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial. Cancer Chemother Pharmacol. 2015 Nov; 76(5):897-907. Morgan RJ, Synold TW, Longmate JA, Quinn DI, Gandara D, Lenz HJ, Ruel C, Xi B, Lewis MD, Colevas AD, Doroshow J, Newman EM. PMID: 26362045.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    102. Assessing the damage control resuscitation: development, drivers and direction. Emerg Med Australas. 2015 Oct; 27(5):485-7. Quinn D, Frith D. PMID: 26315261.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    103. Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma. Br J Cancer. 2015 Aug 11; 113(4):616-25. Yu H, Liu R, Ma B, Li X, Yen HY, Zhou Y, Krasnoperov V, Xia Z, Zhang X, Bove AM, Buscarini M, Parekh D, Gill IS, Liao Q, Tretiakova M, Quinn D, Zhao J, Gill PS. PMID: 26180925.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    104. Relapsed and refractory germ cell tumors: Finessing the rough end of a beautiful story. Urol Oncol. 2015 Aug; 33(8):341-2. Dorff TB, Hu J, Quinn DI. PMID: 26094170.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    105. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2015 May 10; 33(14):1601-8. Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath EI, Lam ET, Gupta S, Lilly MB, Inoue Y, Chi KN, Vogelzang NJ, Quinn DI, Cheng HH, Plymate SR, Hussain M, Tangen CM, Thompson IM. PMID: 25847934.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCellsCTClinical Trials
    106. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015 Apr; 16(4):426-35. Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD. PMID: 25795408.
      View in: PubMed   Mentions: 103     Fields:    Translation:HumansCTClinical Trials
    107. One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer. Cancer Biother Radiopharm. 2015 Jun; 30(5):195-9. Jadvar H, Challa S, Quinn DI, Conti PS. PMID: 25746633.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    108. Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis. J Urol. 2015 Aug; 194(2):378-85. Satkunasivam R, Kim AE, Desai M, Nguyen MM, Quinn DI, Ballas L, Lewinger JP, Stern MC, Hamilton AS, Aron M, Gill IS. PMID: 25711194.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    109. Association of overall survival with glycolytic activity of castrate-resistant prostate cancer metastases. Radiology. 2015 Feb; 274(2):624-5. Jadvar H, Groshen SG, Quinn DI. PMID: 25625748.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    110. Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms. Urol Oncol. 2015 May; 33(5):245-60. Quinn DI, Shore ND, Egawa S, Gerritsen WR, Fizazi K. PMID: 25575714.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    111. Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review. BMC Cancer. 2014 Dec 16; 14:966. Vashistha V, Quinn DI, Dorff TB, Daneshmand S. PMID: 25515347.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    112. Chromoplexy and hypoxic microenvironment drives prostate cancer. Lancet Oncol. 2014 Dec; 15(13):1419-1421. Ballas LK, Hu BR, Quinn DI. PMID: 25456359.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    113. Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors. Cancer Chemother Pharmacol. 2014 Dec; 74(6):1227-34. Piatek CI, Raja GL, Ji L, Gitlitz BJ, Dorff TB, Quinn DI, Hu J, El-Khoueiry AB, Pham HQ, Roman L, Garcia AA. PMID: 25374407.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    114. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. Eur J Cancer. 2014 Dec; 50(18):3145-52. Milowsky MI, Dittrich C, Durán I, Jagdev S, Millard FE, Sweeney CJ, Bajorin D, Cerbone L, Quinn DI, Stadler WM, Rosenberg JE, Lochheed M, Sen P, Squires M, Shi M, Sternberg CN. PMID: 25457633.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    115. Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer. 2015 Apr 15; 136(8):1856-62. Goldkorn A, Ely B, Tangen CM, Tai YC, Xu T, Li H, Twardowski P, Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Garzotto M, Mack PC, Lara P, Higano CS, Hussain M, Vogelzang NJ, Thompson IM, Cote RJ, Quinn DI. PMID: 25219358.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCellsCTClinical Trials
    116. Phase I, dose-escalation study of the targeted cytotoxic LHRH analog AEZS-108 in patients with castration- and taxane-resistant prostate cancer. Clin Cancer Res. 2014 Dec 15; 20(24):6277-83. Liu SV, Tsao-Wei DD, Xiong S, Groshen S, Dorff TB, Quinn DI, Tai YC, Engel J, Hawes D, Schally AV, Pinski JK. PMID: 25278449.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    117. A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2014 Dec; 17(4):359-65. Dorff TB, Groshen S, Tsao-Wei DD, Xiong S, Gross ME, Vogelzang N, Quinn DI, Pinski JK. PMID: 25245366.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCellsCTClinical Trials
    118. Oscillometric blood pressure: a review for clinicians. J Am Soc Hypertens. 2014 Dec; 8(12):930-8. Alpert BS, Quinn D, Gallick D. PMID: 25492837.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    119. The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder. PLoS One. 2014; 9(8):e105326. Li X, Choi WW, Yan R, Yu H, Krasnoperov V, Kumar SR, Schuckman A, Klumpp DJ, Pan CX, Quinn D, Gill IS, Gill PS, Liu R. PMID: 25148033.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    120. Carboplatin's fourth decade: still searching for its sweet spot. Ann Oncol. 2014 Aug; 25(8):1457-8. Quinn DI. PMID: 24950978.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    121. Prolonged fasting reduces IGF-1/PKA to promote hematopoietic-stem-cell-based regeneration and reverse immunosuppression. Cell Stem Cell. 2014 Jun 05; 14(6):810-23. Cheng CW, Adams GB, Perin L, Wei M, Zhou X, Lam BS, Da Sacco S, Mirisola M, Quinn DI, Dorff TB, Kopchick JJ, Longo VD. PMID: 24905167.
      View in: PubMed   Mentions: 135     Fields:    Translation:AnimalsCells
    122. Salvage chemotherapy for refractory germ cell tumors. Oncology (Williston Park). 2014 Jun; 28(6):498-500. Dorff TB, Hu JS, Quinn DI. PMID: 25134324.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    123. Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States. Urol Oncol. 2014 Jul; 32(5):637-44. Apolo AB, Kim JW, Bochner BH, Steinberg SM, Bajorin DF, Kelly WK, Agarwal PK, Koppie TM, Kaag MG, Quinn DI, Vogelzang NJ, Sridhar SS. PMID: 24840869.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    124. A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer. 2014 Sep 01; 120(17):2684-93. Hussain M, Daignault S, Agarwal N, Grivas PD, Siefker-Radtke AO, Puzanov I, MacVicar GR, Levine EG, Srinivas S, Twardowski P, Eisenberger MA, Quinn DI, Vaishampayan UN, Yu EY, Dawsey S, Day KC, Day ML, Al-Hawary M, Smith DC. PMID: 24802654.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    125. Skate park injury: a new mechanism of sternoclavicular joint dislocation. Emerg Med Australas. 2014 Jun; 26(3):316-7. Quinn D. PMID: 24712682.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    126. Effect of mechanical behavior of the brachial artery on blood pressure measurement during cuff inflation and cuff deflation. Blood Press Monit. 2014 Apr; 19(2):120. Dart RA, Alpert B, Quinn D. PMID: 24618886.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    127. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol. 2014 Apr 10; 32(11):1136-42. Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Datar RH, Garzotto M, Mack PC, Lara P, Higano CS, Hussain M, Thompson IM, Cote RJ, Vogelzang NJ. PMID: 24616308.
      View in: PubMed   Mentions: 110     Fields:    Translation:HumansCellsCTClinical Trials
    128. Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. Target Oncol. 2015 Mar; 10(1):45-53. Rini BI, Quinn DI, Baum M, Wood LS, Tarazi J, Rosbrook B, Arruda LS, Cisar L, Roberts WG, Kim S, Motzer RJ. PMID: 24595903.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    129. Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421. J Natl Cancer Inst. 2014 Apr; 106(4):dju013. Lara PN, Ely B, Quinn DI, Mack PC, Tangen C, Gertz E, Twardowski PW, Goldkorn A, Hussain M, Vogelzang NJ, Thompson IM, Van Loan MD. PMID: 24565955.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    130. Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. J Immunother Cancer. 2014; 2:2. Bhatia S, Curti B, Ernstoff MS, Gordon M, Heath EI, Miller WH, Puzanov I, Quinn DI, Flaig TW, VanVeldhuizen P, Byrnes-Blake K, Freeman JA, Bittner R, Hunder N, Souza S, Thompson JA. PMID: 24829759.
      View in: PubMed   Mentions: 16     Fields:    
    131. Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T. Expert Rev Anticancer Ther. 2014 Jan; 14(1):51-61. Quinn DI, Vaishampayan U, Higano CS, Lin DW, Shore ND, Beer TM. PMID: 24224900.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    132. Novel tyrosine kinase inhibitors for renal cell carcinoma. Expert Rev Clin Pharmacol. 2014 Jan; 7(1):67-73. Dorff TB, Pal SK, Quinn DI. PMID: 24308791.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    133. Targeted α-particle therapy of bone metastases in prostate cancer. Clin Nucl Med. 2013 Dec; 38(12):966-71. Jadvar H, Quinn DI. PMID: 24212441.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    134. Durable complete remission from castration-resistant prostate cancer with sipuleucel-T after estrogen withdrawal. Clin Genitourin Cancer. 2014 Apr; 12(2):e55-8. Dorff TB, Wilkins C, Hepgur M, Quinn DI. PMID: 24331572.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    135. Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: a critical analysis of 1,994 patients. Urol Oncol. 2014 Jan; 32(1):52.e1-9. Mitra AP, Skinner EC, Schuckman AK, Quinn DI, Dorff TB, Daneshmand S. PMID: 24239476.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    136. Epidermal growth factor receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3 cases. Urology. 2014 Jan; 83(1):159-65. Brown A, Ma Y, Danenberg K, Schuckman AK, Pinski JK, Pagliaro LC, Quinn DI, Dorff TB. PMID: 24238569.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    137. Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2013 Dec; 11(4):416-22. Dorff TB, Tsao-Wei DD, Groshen S, Boswell W, Goldkorn A, Xiong S, Quinn DI, Pinski JK. PMID: 24099865.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    138. Modulation of allergen-induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy. 2013 Sep; 68(9):1136-42. Oliver A, Bjermer L, Quinn D, Saggu P, Thomas P, Yarnall K, Lötvall J. PMID: 23924233.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    139. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol. 2013 Aug; 14(9):893-900. Quinn DI, Tangen CM, Hussain M, Lara PN, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM. PMID: 23871417.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansCTClinical Trials
    140. Therapeutic windows and opportunity cost cast upon prostate cancer's fatal shore. Ann Oncol. 2013 Jul; 24(7):1717-1720. Goldkorn A, Aparicio AM, Quinn DI. PMID: 23798673.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    141. Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J Nucl Med. 2013 Aug; 54(8):1195-201. Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Pinski JK, Quinn DI. PMID: 23785174.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    142. Tivozanib in the treatment of renal cell carcinoma. Biologics. 2013; 7:139-48. Hepgur M, Sadeghi S, Dorff TB, Quinn DI. PMID: 23788831.
      View in: PubMed   Mentions:
    143. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013 Apr 04; 368(14):1314-25. Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM. PMID: 23550669.
      View in: PubMed   Mentions: 137     Fields:    Translation:Humans
    144. Differentiating mTOR inhibitors in renal cell carcinoma. Cancer Treat Rev. 2013 Nov; 39(7):709-19. Pal SK, Quinn DI. PMID: 23433636.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimalsCells
    145. A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors. Invest New Drugs. 2013 Aug; 31(4):1016-22. Feldman DR, Einhorn LH, Quinn DI, Loriot Y, Joffe JK, Vaughn DJ, Fléchon A, Hajdenberg J, Halim AB, Zahir H, Motzer RJ. PMID: 23417696.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    146. Speeding dating for docetaxel and recent debutantes in castration-resistant prostate cancer: 'plus or minus' may be a minus. Ann Oncol. 2013 Feb; 24(2):270-272. Dorff TB, Quinn DI. PMID: 23341479.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    147. Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol. 2013 Jan 01; 31(1):131-61. Roth BJ, Krilov L, Adams S, Aghajanian CA, Bach P, Braiteh F, Brose MS, Ellis LM, Erba H, George DJ, Gilbert MR, Jacobson JO, Larsen EC, Lichtman SM, Partridge AH, Patel JD, Quinn DI, Robison LL, von Roenn JH, Samlowski W, Schwartz GK, Vogelzang NJ. PMID: 23213095.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    148. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California. Urol Oncol. 2013 Nov; 31(8):1737-43. Fairey AS, Daneshmand S, Quinn D, Dorff T, Dorin R, Lieskovsky G, Schuckman A, Cai J, Miranda G, Skinner EC. PMID: 23141776.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimals
    149. Small cell bladder cancer: biology and management. Semin Oncol. 2012 Oct; 39(5):615-8. Fahed E, Hansel DE, Raghavan D, Quinn DI, Dorff TB. PMID: 23040258.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    150. Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncol. 2012 Oct; 13(10):1055-62. Eisen T, Joensuu H, Nathan PD, Harper PG, Wojtukiewicz MZ, Nicholson S, Bahl A, Tomczak P, Pyrhonen S, Fife K, Bono P, Boxall J, Wagner A, Jeffers M, Lin T, Quinn DI. PMID: 22959186.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    151. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol. 2013 Jan; 63(1):58-66. Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF, Dreicer R, George DJ, Milowsky MI, Theodorescu D, Vaughn DJ, Galsky MD, Soloway MS, Quinn DI, International Consultation on Urologic Disease-European Association of Urology Consultation on Bladd . PMID: 22917984.
      View in: PubMed   Mentions: 73     Fields:    Translation:Humans
    152. Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med. 2012 Jul; 37(7):637-43. Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Gross ME, Pinski JK, Quinn DI. PMID: 22691503.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    153. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012 Jul 10; 30(20):2509-15. Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Jänne PA, Quinn DI, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG, Vogelzang NJ, Chen HX, Stadler WM, Vokes EE. PMID: 22665541.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansCTClinical Trials
    154. Immune response to sipuleucel-T in prostate cancer. Cancers (Basel). 2012 Apr 18; 4(2):420-41. Thara E, Dorff TB, Averia-Suboc M, Luther M, Reed ME, Pinski JK, Quinn DI. PMID: 24213318.
      View in: PubMed   Mentions:
    155. Blood cells and their use in active immunotherapy of prostate cancer. Hum Vaccin Immunother. 2012 Apr; 8(4):528-33. Zhang SY, Thara E, Quinn DI, Dorff TB. PMID: 22370509.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    156. Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm. . 2012 Mar; 11(3):526-37. Pal SK, Williams S, Josephson DY, Carmichael C, Vogelzang NJ, Quinn DI. PMID: 22351744.
      View in: PubMed   Mentions:
    157. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol. 2012 Feb 10; 30(5):507-12. Choueiri TK, Ross RW, Jacobus S, Vaishampayan U, Yu EY, Quinn DI, Hahn NM, Hutson TE, Sonpavde G, Morrissey SC, Buckle GC, Kim WY, Petrylak DP, Ryan CW, Eisenberger MA, Mortazavi A, Bubley GJ, Taplin ME, Rosenberg JE, Kantoff PW. PMID: 22184381.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCTClinical Trials
    158. The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol. 2011 Dec; 9(12 Suppl 28):1-14; quiz 15-6. Armstrong AJ, Ferrari AC, Quinn DI. PMID: 22407145.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    159. FDG PET/CT demonstration of pancreatic metastasis from prostate cancer. Clin Nucl Med. 2011 Oct; 36(10):961-2. Desai B, Elatre W, Quinn DI, Jadvar H. PMID: 21892064.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    160. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol. 2012 Apr; 23(4):968-73. Tolcher AW, Quinn DI, Ferrari A, Ahmann F, Giaccone G, Drake T, Keating A, de Bono JS. PMID: 21859898.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCTClinical Trials
    161. Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. BJU Int. 2012 Mar; 109(6):846-54. Mitra AP, Quinn DI, Dorff TB, Skinner EC, Schuckman AK, Miranda G, Gill IS, Daneshmand S. PMID: 21812902.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    162. Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. Maturitas. 2011 Aug; 69(4):296-303. Thara E, Dorff TB, Pinski JK, Quinn DI. PMID: 21621934.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    163. Using molecular markers to help predict who will fail after radical prostatectomy. Prostate Cancer. 2011; 2011:290160. Swanson GP, Quinn D. PMID: 22096655.
      View in: PubMed   Mentions:
    164. A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma. Int J Clin Oncol. 2011 Oct; 16(5):494-9. Shek D, Longmate J, Quinn DI, Margolin KA, Twardowski P, Gandara DR, Frankel P, Pan CX, Lara PN. PMID: 21431345.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    165. Show us a sign: the search for "game changing" prostate cancer biomarkers. Lancet Oncol. 2011 Mar; 12(3):204-6. Quinn D, Gross M. PMID: 21310657.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    166. Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors. Am J Clin Oncol. 2011 Feb; 34(1):27-31. Iqbal S, Tsao-Wei DD, Quinn DI, Gitlitz BJ, Groshen S, Aparicio A, Lenz HJ, El-Khoueiry A, Pinski J, Garcia AA. PMID: 20142723.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    167. One-year follow-up of collaborative depression care for low-income, predominantly Hispanic patients with cancer. Psychiatr Serv. 2011 Feb; 62(2):162-70. Ell K, Xie B, Kapetanovic S, Quinn DI, Lee PJ, Wells A, Chou CP. PMID: 21285094.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansPHPublic Health
    168. Cabazitaxel in prostate cancer: stretching a string. Lancet. 2010 Oct 02; 376(9747):1119-20. Dorff TB, Quinn DI. PMID: 20888974.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    169. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology. 2010 Oct; 76(4):923-6. Twardowski P, Stadler WM, Frankel P, Lara PN, Ruel C, Chatta G, Heath E, Quinn DI, Gandara DR. PMID: 20646741.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    170. Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. Expert Rev Anticancer Ther. 2010 Jun; 10(6):825-35. Bellmunt J, Fishman M, Eisen T, Quinn D. PMID: 20553208.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    171. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res. 2010 Jun 01; 16(11):3028-34. Dorff TB, Goldman B, Pinski JK, Mack PC, Lara PN, Van Veldhuizen PJ, Quinn DI, Vogelzang NJ, Thompson IM, Hussain MH. PMID: 20484019.
      View in: PubMed   Mentions: 75     Fields:    Translation:HumansCTClinical Trials
    172. Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol. 2011 Apr; 78(1):24-32. Bellmunt J, Eisen T, Fishman M, Quinn D. PMID: 20399677.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    173. Fasting and cancer treatment in humans: A case series report. Aging (Albany NY). 2009 Dec 31; 1(12):988-1007. Safdie FM, Dorff T, Quinn D, Fontana L, Wei M, Lee C, Cohen P, Longo VD. PMID: 20157582.
      View in: PubMed   Mentions: 128     Fields:    Translation:Humans
    174. Perioperative chemotherapy for urothelial cancer: how have we made a "sow's ear" out of a chemotherapy-sensitive tumor? Cancer. 2009 Nov 15; 115(22):5139-42. Dorff TB, Quinn DI. PMID: 19645028.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    175. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol. 2009 Dec 01; 27(34):5788-93. Gordon MS, Hussey M, Nagle RB, Lara PN, Mack PC, Dutcher J, Samlowski W, Clark JI, Quinn DI, Pan CX, Crawford D. PMID: 19884559.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    176. Targeted therapy in renal cancer. Ther Adv Med Oncol. 2009 Nov; 1(3):183-205. Dorff TB, Goldkorn A, Quinn DI. PMID: 21789121.
      View in: PubMed   Mentions:
    177. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs. 2009 Mar; 20(3):179-84. Lara PN, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G, Posadas E, Stadler W, Gandara DR. PMID: 19396016.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCTClinical Trials
    178. An evaluation of the completeness of reporting of childhood tuberculosis. Eur Respir J. 2009 Jul; 34(1):176-9. Teo SS, Alfaham M, Evans MR, Watson JM, Riordan A, Sonnenberg P, Clark J, Hayward A, Sharland M, Moore-Gillon J, Novelli V, Quinn D, Shingadia D, British Paediatric Surveillance Unit Childhood Tuberculosis study group . PMID: 19251788.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansPHPublic Health
    179. Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial. Clin Genitourin Cancer. 2009 Jan; 7(1):43-50. Cheung E, Pinski J, Dorff T, Groshen S, Quinn DI, Reynolds CP, Maurer BJ, Lara PN, Tsao-Wei DD, Twardowski P, Chatta G, McNamara M, Gandara DR. PMID: 19213668.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    180. COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCER. Ther Adv Med Oncol. 2009; 1(2):69-77. Dorff TB, Tangen CM, Crawford ED, Petrylak DP, Higano CS, Raghavan D, Quinn DI, Vogelzang NJ, Thompson IM, Hussain MH. PMID: 21085622.
      View in: PubMed   Mentions:
    181. Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. Clin Pharmacokinet. 2009; 48(3):199-209. Quinn DI, Nemunaitis J, Fuloria J, Britten CD, Gabrail N, Yee L, Acharya M, Chan K, Cohen N, Dudov A. PMID: 19385713.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    182. Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience. World J Urol. 2009 Feb; 27(1):39-44. Dorff TB, Tsao-Wei D, Miranda G, Skinner DG, Stein JP, Quinn DI. PMID: 19020886.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    183. Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. J Urol. 2008 Dec; 180(6):2384-8; discussion 2388. Smith DC, Mackler NJ, Dunn RL, Hussain M, Wood D, Lee CT, Sanda M, Vaishampayan U, Petrylak DP, Quinn DI, Beekman K, Montie JE. PMID: 18930256.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    184. Randomized controlled trial of collaborative care management of depression among low-income patients with cancer. J Clin Oncol. 2008 Sep 20; 26(27):4488-96. Ell K, Xie B, Quon B, Quinn DI, Dwight-Johnson M, Lee PJ. PMID: 18802161.
      View in: PubMed   Mentions: 73     Fields:    Translation:Humans
    185. A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. BJU Int. 2008 Dec; 102(11):1601-6. Chan JS, Beer TM, Quinn DI, Pinski JK, Garzotto M, Sokoloff M, Dehaze DR, Ryan CW. PMID: 18782306.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    186. Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomy. BJU Int. 2008 Nov; 102(9):1086-91. Tagawa ST, Dorff TB, Rochanda L, Ye W, Boyle S, Raghavan D, Lieskovsky G, Skinner DG, Quinn DI, Liebman HA. PMID: 18671791.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    187. The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro. Br J Cancer. 2008 Mar 25; 98(6):1085-93. O'Brien PM, Davies MJ, Scurry JP, Smith AN, Barton CA, Henderson MJ, Saunders DN, Gloss BS, Patterson KI, Clancy JL, Heinzelmann-Schwarz VA, Murali R, Scolyer RA, Zeng Y, Williams ED, Scurr L, Defazio A, Quinn DI, Watts CK, Hacker NF, Henshall SM, Sutherland RL. PMID: 18349819.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    188. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer. 2007 Dec; 5(7):433-7. Chee KG, Longmate J, Quinn DI, Chatta G, Pinski J, Twardowski P, Pan CX, Cambio A, Evans CP, Gandara DR, Lara PN. PMID: 18272025.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    189. A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. Cancer Chemother Pharmacol. 2008 Apr; 61(4):689-94. Stadler WM, Desai AA, Quinn DI, Bukowski R, Poiesz B, Kardinal CG, Lewis N, Makalinao A, Murray P, Torti FM. PMID: 17569043.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    190. Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. J Cancer Res Clin Oncol. 2007 Oct; 133(10):705-11. Margolin K, Synold TW, Lara P, Frankel P, Lacey SF, Quinn DI, Baratta T, Dutcher JP, Xi B, Diamond DJ, Gandara DR. PMID: 17508219.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    191. Pain management, supportive and palliative care in patients with renal cell carcinoma. BJU Int. 2007 May; 99(5 Pt B):1305-12. Turner JS, Cheung EM, George J, Quinn DI. PMID: 17441929.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    192. Improving treatment of depression among low-income patients with cancer: the design of the ADAPt-C study. Gen Hosp Psychiatry. 2007 May-Jun; 29(3):223-31. Ell K, Quon B, Quinn DI, Dwight-Johnson M, Wells A, Lee PJ, Xie B. PMID: 17484939.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    193. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst. 2006 Oct 04; 98(19):1420-4. Henshall SM, Horvath LG, Quinn DI, Eggleton SA, Grygiel JJ, Stricker PD, Biankin AV, Kench JG, Sutherland RL. PMID: 17018789.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    194. Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells. Int J Oncol. 2006 Jul; 29(1):225-35. Plasencia C, Martínez-Balibrea E, Martinez-Cardús A, Quinn DI, Abad A, Neamati N. PMID: 16773204.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    195. Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. Cancer. 2006 Jun 15; 106(12):2624-9. Beer TM, Tangen CM, Nichols CR, Margolin KA, Dreicer R, Stephenson WT, Quinn DI, Raghavan D, Crawford ED. PMID: 16688776.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    196. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol. 2006 Apr; 175(4):1245-52. Xia G, Kumar SR, Hawes D, Cai J, Hassanieh L, Groshen S, Zhu S, Masood R, Quinn DI, Broek D, Stein JP, Gill PS. PMID: 16515971.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    197. Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J Clin Oncol. 2006 Apr 10; 24(11):1712-9. Levine AM, Tulpule A, Quinn DI, Gorospe G, Smith DL, Hornor L, Boswell WD, Espina BM, Groshen SG, Masood R, Gill PS. PMID: 16520466.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    198. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res. 2006 Mar 01; 12(5):1556-63. Lara PN, Stadler WM, Longmate J, Quinn DI, Wexler J, Van Loan M, Twardowski P, Gumerlock PH, Vogelzang NJ, Vokes EE, Lenz HJ, Doroshow JH, Gandara DR. PMID: 16533781.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    199. EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival. Oncogene. 2006 Feb 02; 25(5):769-80. Xia G, Kumar SR, Stein JP, Singh J, Krasnoperov V, Zhu S, Hassanieh L, Smith DL, Buscarini M, Broek D, Quinn DI, Weaver FA, Gill PS. PMID: 16205642.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCells
    200. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. J Thorac Oncol. 2006 Feb; 1(2):126-34. Lara PN, Koczywas M, Quinn DI, Lenz HJ, Davies AM, Lau DH, Gumerlock PH, Longmate J, Doroshow JH, Schenkein D, Kashala O, Gandara DR. PMID: 17409841.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    201. Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis. Invest New Drugs. 2006 Jan; 24(1):79-83. Garcia AA, Iqbal S, Quinn D, Edwards S, Lenz HJ, Weber J. PMID: 16379039.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    202. Cytokine therapy: a standard of care for metastatic renal cell carcinoma? Clin Genitourin Cancer. 2005 Dec; 4(3):181-6. Hutson TE, Quinn DI. PMID: 16425986.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    203. Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases. J Urol. 2005 Nov; 174(5):1808-13; discussion 1813. Raghavan D, Brandes LJ, Klapp K, Snyder T, Styles E, Tsao-Wei D, Lieskovsky G, Quinn DI, Ramsey EW. PMID: 16217292.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    204. Postchemotherapy residual masses in advanced seminoma: current management and outcomes. Expert Rev Anticancer Ther. 2005 Oct; 5(5):869-74. Quek ML, Simma-Chiang V, Stein JP, Pinski J, Quinn DI, Skinner DG. PMID: 16221056.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    205. Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines. . 2005 Jul; 4(7):1105-13. Plasencia C, Dayam R, Wang Q, Pinski J, Burke TR, Quinn DI, Neamati N. PMID: 16020668.
      View in: PubMed   Mentions:
    206. Up-regulation of EphB4 in mesothelioma and its biological significance. Clin Cancer Res. 2005 Jun 15; 11(12):4305-15. Xia G, Kumar SR, Masood R, Koss M, Templeman C, Quinn D, Zhu S, Reddy R, Krasnoperov V, Gill PS. PMID: 15958611.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    207. EphB4 expression and biological significance in prostate cancer. Cancer Res. 2005 Jun 01; 65(11):4623-32. Xia G, Kumar SR, Masood R, Zhu S, Reddy R, Krasnoperov V, Quinn DI, Henshall SM, Sutherland RL, Pinski JK, Daneshmand S, Buscarini M, Stein JP, Zhong C, Broek D, Roy-Burman P, Gill PS. PMID: 15930280.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansAnimalsCells
    208. The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy. Urol Clin North Am. 2005 May; 32(2):217-30, vii. Aparicio AM, Elkhouiery AB, Quinn DI. PMID: 15862619.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    209. Molecular prognostic factors in bladder cancer. BJU Int. 2005 Apr; 95(6):739-42. Buscarini M, Quek ML, Gill P, Xia G, Quinn DI, Stein JP. PMID: 15794774.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    210. Molecular markers of prostate cancer outcome. Eur J Cancer. 2005 Apr; 41(6):858-87. Quinn DI, Henshall SM, Sutherland RL. PMID: 15808955.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCells
    211. Angiogenesis-targeted therapies in prostate cancer. Clin Prostate Cancer. 2004 Dec; 3(3):165-73. Lara PN, Twardowski P, Quinn DI. PMID: 15636683.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    212. Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. Cancer. 2004 Jun 15; 100(12):2627-36. Newell ME, Hoy JF, Cooper SG, DeGraaff B, Grulich AE, Bryant M, Millar JL, Brew BJ, Quinn DI. PMID: 15197806.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    213. Microscopic and gross extravesical extension in pathological staging of bladder cancer. J Urol. 2004 Feb; 171(2 Pt 1):640-5. Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Cote RJ, Lieskovsky G, Quinn DI, Skinner DG. PMID: 14713777.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    214. Is year of radical prostatectomy a predictor of outcome in prostate cancer? J Urol. 2004 Feb; 171(2 Pt 1):692-6. Cagiannos I, Karakiewicz P, Graefen M, Eastham JA, Ohori M, Rabbani F, Reuter V, Wheeler T, Kupelian P, Klein E, Huland H, Hammerer PG, Erbersdobler A, Schroeder F, Wildhagen M, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Morash CG, Scardino PT, Kattan MW. PMID: 14713788.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    215. The future in advanced prostate cancer: take your partners or is the last dance for me? Rev Urol. 2004; 6 Suppl 10:S29-44. Quinn DI. PMID: 16985929.
      View in: PubMed   Mentions:
    216. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol. 2003 Nov; 170(5):1798-803. Cagiannos I, Karakiewicz P, Eastham JA, Ohori M, Rabbani F, Gerigk C, Reuter V, Graefen M, Hammerer PG, Erbersdobler A, Huland H, Kupelian P, Klein E, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Morash CG, Scardino PT, Kattan MW. PMID: 14532779.
      View in: PubMed   Mentions: 74     Fields:    Translation:Humans
    217. SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res. 2003 Oct 15; 9(13):4772-81. Lara PN, Quinn DI, Margolin K, Meyers FJ, Longmate J, Frankel P, Mack PC, Turrell C, Valk P, Rao J, Buckley P, Wun T, Gosselin R, Galvin I, Gumerlock PH, Lenz HJ, Doroshow JH, Gandara DR, California Cancer Consortium . PMID: 14581348.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCellsCTClinical Trials
    218. Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. Oncogene. 2003 Sep 04; 22(38):6005-12. Henshall SM, Afar DE, Rasiah KK, Horvath LG, Gish K, Caras I, Ramakrishnan V, Wong M, Jeffry U, Kench JG, Quinn DI, Turner JJ, Delprado W, Lee CS, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Stricker PD, Grygiel JJ, Mack DH, Sutherland RL. PMID: 12955079.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    219. Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer. 2003 Sep 01; 98(5):955-61. Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Lieskovsky G, Quinn DI, Raghavan D, Skinner DG. PMID: 12942562.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    220. A randomized, prospective clinical trial to assess the potential infection risk associated with the PosiFlow needleless connector. J Hosp Infect. 2003 Aug; 54(4):288-93. Casey AL, Worthington T, Lambert PA, Quinn D, Faroqui MH, Elliott TS. PMID: 12919759.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    221. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res. 2003 Jul 15; 63(14):4196-203. Henshall SM, Afar DE, Hiller J, Horvath LG, Quinn DI, Rasiah KK, Gish K, Willhite D, Kench JG, Gardiner-Garden M, Stricker PD, Scher HI, Grygiel JJ, Agus DB, Mack DH, Sutherland RL. PMID: 12874026.
      View in: PubMed   Mentions: 79     Fields:    Translation:HumansAnimals
    222. Molecular prognostication in bladder cancer--a current perspective. Eur J Cancer. 2003 Jul; 39(11):1501-10. Quek ML, Quinn DI, Daneshmand S, Stein JP. PMID: 12855255.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    223. Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion. Cancer. 2003 Apr 15; 97(8):1884-93. Quinn DI, Henshall SM, Brenner PC, Kooner R, Golovsky D, O'Neill GF, Turner JJ, Delprado W, Grygiel JJ, Sutherland RL, Stricker PD. PMID: 12673714.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    224. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A. 2003 Mar 18; 100(6):3410-5. Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR, Ward RL, Hawkins NJ, Quinn DI, Russell PJ, Sutherland RL, Breit SN, Moskaluk CA, Frierson HF, Hampton GM. PMID: 12624183.
      View in: PubMed   Mentions: 132     Fields:    Translation:Humans
    225. Downregulation of KAI1 mRNA in localised prostate cancer and its bony metastases does not correlate with p53 overexpression. Prostate Cancer Prostatic Dis. 2003; 6(2):174-81. Jackson P, Ow K, Yardley G, Delprado W, Quinn DI, Yang JL, Russell PJ. PMID: 12806379.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    226. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2002 Aug 01; 20(15):3206-12. Graefen M, Karakiewicz PI, Cagiannos I, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Klein E, Kupelian P, Skinner DG, Lieskovsky G, Bochner B, Huland H, Hammerer PG, Haese A, Erbersdobler A, Eastham JA, de Kernion J, Cangiano T, Schröder FH, Wildhagen MF, van der Kwast TH, Scardino PT, Kattan MW. PMID: 12149292.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    227. Surgery and adjunctive chemotherapy for invasive bladder cancer. Surg Oncol. 2002 Jun; 11(1-2):55-63. Raghavan D, Quinn D, Skinner DG, Stein JP. PMID: 12031868.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    228. Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol. 2002 Feb 15; 20(4):951-6. Graefen M, Karakiewicz PI, Cagiannos I, Klein E, Kupelian PA, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, de Kernion J, Cangiano T, Schröder FH, Wildhagen MF, Scardino PT, Kattan MW. PMID: 11844816.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    229. Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models. J Clin Oncol. 2001 Aug 15; 19(16):3692-705. Quinn DI, Henshall SM, Haynes AM, Brenner PC, Kooner R, Golovsky D, Mathews J, O'Neill GF, Turner JJ, Delprado W, Finlayson JF, Sutherland RL, Grygiel JJ, Stricker PD. PMID: 11504751.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    230. Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res. 2001 Jul 15; 61(14):5331-5. Horvath LG, Henshall SM, Lee CS, Head DR, Quinn DI, Makela S, Delprado W, Golovsky D, Brenner PC, O'Neill G, Kooner R, Stricker PD, Grygiel JJ, Gustafsson JA, Sutherland RL. PMID: 11454669.
      View in: PubMed   Mentions: 83     Fields:    Translation:Humans
    231. The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2001 Mar 01; 344(9):686; author reply 687-8. Quinn DI. PMID: 11229338.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    232. Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients. Clin Cancer Res. 2001 Mar; 7(3):544-50. Henshall SM, Quinn DI, Lee CS, Head DR, Golovsky D, Brenner PC, Delprado W, Stricker PD, Grygiel JJ, Sutherland RL. PMID: 11297246.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    233. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res. 2001 Jan 15; 61(2):423-7. Henshall SM, Quinn DI, Lee CS, Head DR, Golovsky D, Brenner PC, Delprado W, Stricker PD, Grygiel JJ, Sutherland RL. PMID: 11212224.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCells
    234. Effect of less frequent bathing of preterm infants on skin flora and pathogen colonization. J Obstet Gynecol Neonatal Nurs. 2000 Nov-Dec; 29(6):584-9. Franck LS, Quinn D, Zahr L. PMID: 11110328.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsCTClinical Trials
    235. What progress has been made in meeting the needs of seriously maltreated children? The course of 200 cases through the Boston Juvenile Court. Child Abuse Negl. 2000 May; 24(5):599-610. Bishop SJ, Murphy JM, Hicks R, Quinn D, Lewis PJ, Grace M, Jellinek MS. PMID: 10819093.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    236. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Res. 2000 Mar 15; 60(6):1585-94. Quinn DI, Henshall SM, Head DR, Golovsky D, Wilson JD, Brenner PC, Turner JJ, Delprado W, Finlayson JF, Stricker PD, Grygiel JJ, Sutherland RL. PMID: 10749127.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    237. Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer Res. 1999 Oct; 5(10):2810-9. Bova RJ, Quinn DI, Nankervis JS, Cole IE, Sheridan BF, Jensen MJ, Morgan GJ, Hughes CJ, Sutherland RL. PMID: 10537346.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    238. Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer. Cancer Res. 1999 May 15; 59(10):2324-8. Ricciardelli C, Quinn DI, Raymond WA, McCaul K, Sutherland PD, Stricker PD, Grygiel JJ, Sutherland RL, Marshall VR, Tilley WD, Horsfall DJ. PMID: 10344737.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    239. Analysis of diagnostic metabolites by capillary electrophoresis-mass spectrometry. J Chromatogr B Biomed Sci Appl. 1999 Apr 30; 727(1-2):43-52. He T, Quinn D, Fu E, Wang YK. PMID: 10360421.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    240. Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience. Cancer. 1999 Apr 15; 85(8):1758-64. Veness MJ, Quinn DI, Ong CS, Keogh AM, Macdonald PS, Cooper SG, Morgan GW. PMID: 10223570.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    241. Acute renal impairment after immersion and near-drowning. J Am Soc Nephrol. 1999 Feb; 10(2):382-6. Spicer ST, Quinn D, Nyi Nyi NN, Nankivell BJ, Hayes JM, Savdie E. PMID: 10215339.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    242. An audit of oestrogen implant hormone replacement therapy. Aust N Z J Obstet Gynaecol. 1998 Nov; 38(4):455-60. Templeman C, Quinn D, Hansen R, Moreton T, Baber R. PMID: 9890234.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    243. Granulosa cell tumors express erbB4 and are sensitive to the cytotoxic action of heregulin-beta2/PE40. Cancer Res. 1998 May 01; 58(9):1773-8. Furger C, Fiddes RJ, Quinn DI, Bova RJ, Daly RJ, Sutherland RL. PMID: 9581810.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    244. Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users. Clin Pharmacokinet. 1997 Nov; 33(5):344-400. Quinn DI, Wodak A, Day RO. PMID: 9391747.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    245. The changing radiographic presentation of bronchogenic carcinoma with reference to cell types. Chest. 1996 Dec; 110(6):1474-9. Quinn D, Gianlupi A, Broste S. PMID: 8989064.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    246. Using patient feedback for creating and improving innovative programs. J Healthc Qual. 1996 Jul-Aug; 18(4):26-32. Quinn D. PMID: 10172679.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    247. Drug interactions of clinical importance. An updated guide. Drug Saf. 1995 Jun; 12(6):393-452. Quinn DI, Day RO. PMID: 8527014.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    248. Adverse drug reactions and their measurement in the rheumatic diseases. J Rheumatol. 1995 May; 22(5):983-8. Day RO, Quinn DI, Conaghan PG, Tett SE. PMID: 8587095.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    249. Radionuclide hepatobiliary scanning in patients with AIDS-related sclerosing cholangitis. Clin Nucl Med. 1993 May; 18(5):417-22. Quinn D, Pocock N, Freund J, Kelleher A, Penny R, Brew B. PMID: 8508578.
      View in: PubMed   Mentions:    Fields:    Translation:Humans